Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study
Abstract Background Genitourinary small cell carcinoma is rare, and has a poor prognosis. However, effective treatment options for this disease are limited. We present a study to assess the efficacy of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11473-2 |
| _version_ | 1797559027929972736 |
|---|---|
| author | Riqing Huang Meiting Chen Haifeng Li Xin An Cong Xue Anqi Hu Ditian Shu Wei Yang Fangjian Zhou Dan Sui Kai Yao Yonghong Li Zhiming Wu Zhiyong Li Zhuowei Liu Yanxia Shi |
| author_facet | Riqing Huang Meiting Chen Haifeng Li Xin An Cong Xue Anqi Hu Ditian Shu Wei Yang Fangjian Zhou Dan Sui Kai Yao Yonghong Li Zhiming Wu Zhiyong Li Zhuowei Liu Yanxia Shi |
| author_sort | Riqing Huang |
| collection | DOAJ |
| description | Abstract Background Genitourinary small cell carcinoma is rare, and has a poor prognosis. However, effective treatment options for this disease are limited. We present a study to assess the efficacy of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma (GSCC). Methods We performed a retrospective analysis of patients with locally advanced or metastatic GSCC from Jan 2013 to September 2022 at Sun Yat-sen University Cancer Center. The survival and safety profiles were analyzed. Results Forty-two GSCC patients were enrolled, which included 20 with chemotherapy plus immunotherapy and 22 with chemotherapy alone. The median follow-up time was 15.13 months (95% CI, 8.84–21.42). The addition of immunotherapy to chemotherapy demonstrated no significant difference in median progression-free survival (p = 0.37). However, the median overall survival (OS) was 22.97 and 14.03 months with immunotherapy plus chemotherapy and chemotherapy alone, respectively (HR = 0.69, 95%CI 0.08–0.55, p = 0.017). Two patients with immunotherapy plus chemotherapy achieved clinical complete remission. The overall response rate for patients receiving chemotherapy combined with immunotherapy was 65%, which was higher in comparison to those treated with chemotherapy alone (50%). Univariate and multivariate analyses demonstrated that chemotherapy combined with immunotherapy independently achieved favorable OS. Four patients experienced immunotherapy-related adverse events, with one developing grade 3 hypothyroidism. Conclusions Among patients with locally advanced or metastatic GSCC, immunotherapy combined with chemotherapy might be thought of as a potentially effective treatment option for patients with GSCC. |
| first_indexed | 2024-03-10T17:39:54Z |
| format | Article |
| id | doaj.art-7346b4d9bb664fbc8cafcd2f668eb50b |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-10T17:39:54Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-7346b4d9bb664fbc8cafcd2f668eb50b2023-11-20T09:43:44ZengBMCBMC Cancer1471-24072023-10-012311910.1186/s12885-023-11473-2Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective studyRiqing Huang0Meiting Chen1Haifeng Li2Xin An3Cong Xue4Anqi Hu5Ditian Shu6Wei Yang7Fangjian Zhou8Dan Sui9Kai Yao10Yonghong Li11Zhiming Wu12Zhiyong Li13Zhuowei Liu14Yanxia Shi15State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterThe Fourth People’s Hospital of ShenyangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterAbstract Background Genitourinary small cell carcinoma is rare, and has a poor prognosis. However, effective treatment options for this disease are limited. We present a study to assess the efficacy of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma (GSCC). Methods We performed a retrospective analysis of patients with locally advanced or metastatic GSCC from Jan 2013 to September 2022 at Sun Yat-sen University Cancer Center. The survival and safety profiles were analyzed. Results Forty-two GSCC patients were enrolled, which included 20 with chemotherapy plus immunotherapy and 22 with chemotherapy alone. The median follow-up time was 15.13 months (95% CI, 8.84–21.42). The addition of immunotherapy to chemotherapy demonstrated no significant difference in median progression-free survival (p = 0.37). However, the median overall survival (OS) was 22.97 and 14.03 months with immunotherapy plus chemotherapy and chemotherapy alone, respectively (HR = 0.69, 95%CI 0.08–0.55, p = 0.017). Two patients with immunotherapy plus chemotherapy achieved clinical complete remission. The overall response rate for patients receiving chemotherapy combined with immunotherapy was 65%, which was higher in comparison to those treated with chemotherapy alone (50%). Univariate and multivariate analyses demonstrated that chemotherapy combined with immunotherapy independently achieved favorable OS. Four patients experienced immunotherapy-related adverse events, with one developing grade 3 hypothyroidism. Conclusions Among patients with locally advanced or metastatic GSCC, immunotherapy combined with chemotherapy might be thought of as a potentially effective treatment option for patients with GSCC.https://doi.org/10.1186/s12885-023-11473-2Genitourinary small cell carcinomaMetastaticImmunotherapyChemotherapyEfficacy |
| spellingShingle | Riqing Huang Meiting Chen Haifeng Li Xin An Cong Xue Anqi Hu Ditian Shu Wei Yang Fangjian Zhou Dan Sui Kai Yao Yonghong Li Zhiming Wu Zhiyong Li Zhuowei Liu Yanxia Shi Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study BMC Cancer Genitourinary small cell carcinoma Metastatic Immunotherapy Chemotherapy Efficacy |
| title | Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study |
| title_full | Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study |
| title_fullStr | Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study |
| title_full_unstemmed | Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study |
| title_short | Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study |
| title_sort | effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma a real world retrospective study |
| topic | Genitourinary small cell carcinoma Metastatic Immunotherapy Chemotherapy Efficacy |
| url | https://doi.org/10.1186/s12885-023-11473-2 |
| work_keys_str_mv | AT riqinghuang effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT meitingchen effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT haifengli effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT xinan effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT congxue effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT anqihu effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT ditianshu effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT weiyang effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT fangjianzhou effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT dansui effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT kaiyao effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT yonghongli effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT zhimingwu effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT zhiyongli effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT zhuoweiliu effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy AT yanxiashi effectofchemotherapyaloneorcombinedwithimmunotherapyforlocallyadvancedormetastaticgenitourinarysmallcellcarcinomaarealworldretrospectivestudy |